• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
TLR Agonists Other Products
You are here: Product Lines > Inflammation > TLR Agonists Other Products
Toolbar - View Selection
 
Items 16 of 16
ALX-522-058 Revised 05-Jun-08
Flagellin (high purity)
Add to Clipboard
SYNONYMS FliC (high purity)
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-522-058-C010   10 µg 298.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
SOURCE/HOST: Isolated from Salmonella typhimurium strain 14028.
CONCENTRATION: 0.1mg/ml after reconstitution.
PURITY: ≥95% (SDS-PAGE)
FORMULATION: Lyophilized. Contains PBS.
ENDOTOXIN CONTENT: <0.1EU/µg purified protein (LAL test; Bio Whittaker).
RECONSTITUTION: Reconstitute with 100µl sterile water.
SPECIFICITY: Binds to human and mouse TLR5 (Toll-like receptor 5).
BIOLOGICAL ACTIVITY: Activation of TLR5 in human epithelial cell assays based on NF-κB luciferase fusions, on expression of IL-8 (CXCL8), CCL20, inducible nitric oxide synthase, β-defensin 2 and matrilysin (MMP-7). Maturation of dendritic cells in in vitro and in vivo assays. Adjuvant activity on foreign antigens delivered by subcutaneous and intranasal routes in mice.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 6 months after receipt when stored at -20°C.
HANDLING: After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Product Images
Please click on thumbnails to enlarge.
Product Specific Literature References
Flagellin stimulation of intestinal epithelial cells triggers CCL20-mediated migration of dendritic cells: F. Sierro, et al.; PNAS 98, 13722 (2001) Abstract; Full Text
Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation: S.H. Rhee, et al.; PNAS 102, 13610 (2005) Abstract
General Information
Motile bacteria produce flagella, filaments composed mainly of the structural subunit flagellin. Flagellins are highly conserved molecules among both gram negative and gram positive bacteria, especially in 170 N-terminal and 100 C-terminal amino acids. In mammalian cells, Toll-like receptor 5 (TLR5) senses various flagellins resulting in activation of innate and adaptive immunity. The phase 1 flagellin FliC from Salmonella typhimurium (serotype H 'I'), a protein of 494 amino acids, upregulates production of chemokines and antimicrobial compounds in human epithelial cells and monocytes and induces maturation of dendritic cells.
BACKGROUND/TECHNICAL INFORMATION Swiss-Prot link P06179: Flagellin (Salmonella typhimurium)
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5: F. Hayashi, et al.; Nature 410, 1099 (2001) Abstract
Salmonella typhimurium translocates flagellin across intestinal epithelia, inducing a proinflammatory response: A.T. Gewirtz, et al.; J. Clin. Invest. 107, 99 (2001) Abstract
Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression: A.T. Gewirtz, et al.; J. Immunol. 167, 1882 (2001) Abstract
Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein: T.D. Eaves-Pyles, et al.; J. Immunol. 167, 7009 (2001) Abstract
Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction: T. Eaves-Pyles, et al.; J. Immunol. 166, 1248 (2001) Abstract
Enteroaggregative Escherichia coli expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells: T.S. Steiner, et al.; J. Clin. Invest. 105, 1769 (2000) Abstract
Salmonella flagellin induces tumor necrosis factor alpha in a human promonocytic cell line: F. Ciacci-Woolwine, et al.; Infect. Immun. 66, 1127 (1998) Abstract
Locations of terminal segments of flagellin in the filament structure and their roles in polymerization and polymorphism: Y. Mimori-Kiyosue, et al.; J. Mol. Biol. 270, 222 (1997) Abstract
Further Categories Containing This Product:
Natural Proteins
 
 
ALX-420-040 Revised 05-Mar-07
Gardiquimod
Add to Clipboard
SYNONYMS 1-(4-Amino-2-ethylaminomethylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-420-040-M025   25 mg 130.00 USD Add To Cart
ALX-420-040-M100   100 mg 390.00 USD Add To Cart
Product Specification
FORMULA: C17H23N5O
MW: 313.4
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO (>40mg/ml), dioxane (7mg/ml), methanol (>40mg/ml) or acetonitrile (2mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Selective ligand for human or mouse Toll-like receptor 7 (TLR7). Induces the activation of NF-κB in HEK 293 cells expressing TLR7. At high concentrations (3µg/ml) slightly activates TLR8. More active than Imiquimod (Prod. No. ALX-420-039).
 
 
ALX-420-039 Revised 14-Aug-08
Imiquimod
Add to Clipboard
SYNONYMS 1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
R-837
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-420-039-M100   100 mg 55.00 USD Add To Cart
ALX-420-039-M250   250 mg 120.00 USD Add To Cart
Product Specification
FORMULA: C14H16N4
MW: 240.3
CAS NUMBER: 99011-02-6
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in DMSO (3mg/ml) or dimethyl formamide; slightly soluble in water (warm to 37°C, vortex); insoluble in 100% ethanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for up to 1 year after receipt when stored at -20°C. Stock solutions are stable for up to 3 months when stored at -20°C.
HANDLING: After reconstitution, prepare aliquots and store at -20°C.

Product Description
Topical immune response modifier that inhibits angiogenesis. Up-regulates IL-18 and down-regulates MMP-9 through recognition of Toll-like receptor 7 (TLR7) and subsequent activation of MyD88-dependent pathway.
Product Specific Literature References
Imiquimod applied topically: a novel immune response modifier and new class of drug: R.L. Miller, et al.; Int. J. Immunopharmacol. 21, 1 (1999) Abstract
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002) Abstract
In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases: C. Hesling, et al.; Br. J. Dermatol. 150, 761 (2004) Abstract
Imiquimod as an antiangiogenic agent: V.W. Li, et al.; J. Drugs Dermatol. 4, 708 (2005) Abstract
Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis: S. Majewski, et al.; Int. J. Dermatol. 44, 14 (2005) Abstract
General Information
BACKGROUND/TECHNICAL INFORMATION Stimulation of TLR7 can be achieved with 1-10µg/ml of the compound for 6 to 24 hours.

Related Products:
- ddWater (endotoxin-free) (Prod. No. ALX-505-008)
- PBS (endotoxin-free) (Prod. No. ALX-505-007)
Related Products
Further Categories Containing This Product:
Antitumor Agents (Apoptosis Inducers) • Angiogenesis Modulators Other Products • MMPs Other Products • Inflammasome
 
 
ALX-480-097 Revised 02-Mar-07
Loxoribine
Add to Clipboard
SYNONYMS 7-Allyl-8-oxoguanosine
RWJ 21757
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-480-097-M025   25 mg 120.00 USD Add To Cart
ALX-480-097-M100   100 mg 360.00 USD Add To Cart
Product Specification
FORMULA: C13H17N5O6
MW: 339.3
CAS NUMBER: 121288-39-9
PURITY: ≥97% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO (30mg/ml), water (10mg/ml), water:acetonitrile (1:1) (20mg/ml) or water:methanol (1:1) (10mg/ml).
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Selective ligand for Toll-like receptor 7 (TLR7) via IFN. Activates natural killer cells and primes cytolytic precursor cells for activation by IL-2.
Product Specific Literature References
Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2: B.L. Pope, et al.; J. Immunol. 151, 3007 (1993) Abstract
Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle: M.G. Goodman, et al.; Blood 84, 3457 (1994) Abstract; Full Text
Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression: U. Schindler and V.R. Baichwal; Mol. Cell. Biol. 14, 5820 (1994) Abstract; Full Text
The immunostimulatory compound 7-allyl-8-oxoguanosine (loxoribine) induces a distinct subset of murine cytokines: B.L. Pope, et al.; Cell. Immunol. 162, 333 (1995) Abstract
Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7: J. Lee, et al.; PNAS 100, 6646 (2003) Abstract; Full Text
Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN: I.B. Bekeredjian-Ding, et al.; J. Immunol. 174, 4043 (2005) Abstract; Full Text
 
 
ALX-162-034 Revised 03-Jul-08 New product
MALP-2 (BULK)
Add to Clipboard
SYNONYMS Macrophage-activating Lipopeptide-2
S-[2,3-bis(Palmityloxy)-(2R)-propyl-cysteinyl-GNNDESNISFKEK]
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-034-C500   500 µg 1'250.00 USD Add To Cart
Product Specification
FORMULA: C99H167N19O30S
MW: 2135.2
SOURCE/HOST: Synthetic.
CONCENTRATION: 1mg/ml
PURITY DETAIL: HPLC purified
FORMULATION: Liquid. Pyrogen-free, sterile solution in 33% (v/v) 2-propanol/water.
BIOLOGICAL ACTIVITY: Stimulates macrophages, monocytes and other TLR2 and TLR6 expressing cells in vitro at pg/ml concentrations (e.g. mouse macrophages: 50pg/ml; fibroblasts: 2ng/ml) to release various mediators. Human monocytes require about 10-100x higher concentrations for optimal cytokine or chemokine release than mouse PECS (see [12]). In vivo active at 0.5-5μg (e.g 0.5μg/20g mouse). The presence of 50mM octyl glucoside as carrier gives rise to a higher activity.
SHIPPING: SHIPPED ON DRY ICE
SHORT TERM STORAGE: -20°C
LONG TERM STORAGE: -80°C
USE/STABILITY: Stable for at least 3 years when stored at -20°C. This stock solution is stable for many months when kept in the refrigerator. MALP-2 solutions in the presene of carrier (50mM octyl glucoside, see Background/Technical Information below) are stable at +4°C at least 6 weeks. Some (10%) decrease of activity may occur shortly after transfer into new vessels. This is not due to decomposition but to adsorption (see below). Storage at room temperature for short periods of time does not influence bioactivity. When deep-frozen, MALP-2 does not loose activity within years.
HANDLING: Avoid freeze/thaw cycles. Avoid accidental injection, extreme care should be taken with hypodermic syringes. Avoid inhalation and prevent this compound from entering the bloodstream.
HAZARD: TOXIC.
Product Description
MALP-2 was originally isolated from Mycoplasma fermentans. This MALP-2 corresponds to the originally isolated isomer, which expresses potent endotoxin-like activity and approaches in certain experimental systems the toxicity of LPS. For description of the stereochemistry of MALP-2 (see [7]). MALP-2 signalling, unlike that of LPS, is not transduced via TLR4, but is induced via TLR2 and TLR6 signalling.
For more information about MALP-2 see www.malp-research.de.
New BULK size (500μg) of biologically active, pyrogen-free and sterile MALP-2 for in vitro and animal in vivo studies.
Product Specific Literature References
[1] Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6: P.F. Muhlradt and M. Frisch; Infect. Immun. 62, 3801 (1994) Abstract
[2] Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration: P.F. Mühlradt, et al.; J. Exp. Med. 185, 1951 (1997) Abstract; Full Text
[3] MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?: C. Galanos, et al.; J. Endotox. Res. 6, 471 (2000) Abstract
[4] Discrimination of bacterial lipoproteins by Toll-like receptor 6: O. Takeuchi, et al.; Int. Immunol. 13, 933 (2001) Abstract
[5] In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application: A. Luhrmann, et al.; Infect. Immun. 70, 3785 (2002) Abstract; Full Text
[6] The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant: F. Rharbaoui, et al.; Eur. J. Immunol. 32, 2857 (2002) Abstract
[7] Differential recognition of structural details of bacterial lipopeptides by toll-like receptors: M. Morr, et al.; Eur. J. Immunol. 32, 3337 (2002) Abstract
[8] CD14 is required for MyD88-independent LPS signaling: Z. Jiang, et al.; Nat. Immunol. 6, 565 (2005) Abstract
[9] The tumor suppressor CYLD Acts as a Negative Regulator for Toll-like Receptor 2 Signaling via Negative Cross-talk with TRAF6 and TRAF7: H. Yoshida, et al.; J. Biol. Chem. 280, 41111 (2005) Abstract; Full Text
[10] IRF-7 is the master regulator of type-I interferon-dependent immune responses: K. Honda, et al.; Nature 434, 772 (2005) Abstract
[11] The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies: N. Satta, et al.; Blood 109, 1507 (2007) Abstract
[12] Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2: A. Kaufmann, et al.; Infect. Immun. 67, 6303 (1999) Abstract; Full Text
General Information
BACKGROUND/TECHNICAL INFORMATION MALP-2 sticks avidly to glass or plastic. Since it is active at very low concentrations, i.e. at high dilutions, these low amounts of material tend to become adsorbed to pipette tips and plastic or glass containers. To avoid this, prepare several dilution steps of the MALP-2 stock solution with medium containing 5% autologous serum or buffers with 2% HSA. The presence of 50mM octyl glucoside in the first dilution step is often beneficial and gives rise to higher activity. Avoid small volumes in large vessels. Do not filter.
Because of the ester-bound fatty acids, MALP-2 is sensitive to alkali or acid. The medium should be preconditioned in the CO2 incubator in order to ensure that the pH does not become alkaline. Add cells in preconditioned medium as soon as possible and incubate.
MANUFACTURER Licensed from GBF Braunschweig, Germany.
General Literature References
Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages: T. Into, et al.; Infect. Immun. 70, 3586 (2002) Abstract; Full Text
Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans: K.L. Davis & K.S. Wise; Infect. Immun. 70, 1129 (2002) Abstract; Full Text
Related Products
Further Categories Containing This Product:
Peptides
 
 
ALX-162-027 Revised 30-Jun-08
MALP-2
Add to Clipboard
SYNONYMS Macrophage-activating Lipopeptide-2
S-[2,3-bis(Palmityloxy)-(2R)-propyl-cysteinyl-GNNDESNISFKEK]
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLR Agonists Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-162-027-C050   50 µg 310.00 USD Add To Cart
Product Specification
FORMULA: C99H167N19O30S
MW: 2135.2
SOURCE/HOST: Synthetic.
QUANTITY: 1x107units.
CONCENTRATION: 0.1mg/ml
FORMULATION: Liquid. Sterile solution in PBS containing 2.5% (v/v) 2-propanol, 25mM n-octyl-β-D-glucopyranoside and 1% (wt/v) human serum albumin.
ACTIVITY: Specific activity is ~2x108units/mg. One unit is defined as the dilution giving half maximal release of nitric oxide from C3H/HeJ mouse peritoneal exudate cells in the standard assay (see [1]).
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: -20°C
LONG TERM STORAGE: -80°C
USE/STABILITY: Stable for at least 2 years when stored at -20°C.
HANDLING: Avoid freeze/thaw cycles. Avoid accidental injection, extreme care should be taken with hypodermic syringes. Avoid inhalation and prevent this compound from entering the bloodstream.
HAZARD: TOXIC.
Product Description
MALP-2 was originally isolated from Mycoplasma fermentans. This MALP-2 corresponds to the originally isolated isomer, which expresses potent endotoxin-like activity and approaches in certain experimental systems the toxicity of LPS. For description of the stereochemistry of MALP-2 (see [7]). MALP-2 signalling, unlike that of LPS, is not transduced via TLR4, but is induced via TLR2 and TLR6 signalling.
For more information about MALP-2 see www.malp-research.de.
Product Specific Literature References
[1] Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6: P.F. Muhlradt and M. Frisch; Infect. Immun. 62, 3801 (1994) Abstract
[2] Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration: P.F. Mühlradt, et al.; J. Exp. Med. 185, 1951 (1997) Abstract; Full Text
[3] MALP-2, a Mycoplasma lipopeptide with classical endotoxic properties: end of an era of LPS monopoly?: C. Galanos, et al.; J. Endotox. Res. 6, 471 (2000) Abstract
[4] Discrimination of bacterial lipoproteins by Toll-like receptor 6: O. Takeuchi, et al.; Int. Immunol. 13, 933 (2001) Abstract
[5] In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application: A. Luhrmann, et al.; Infect. Immun. 70, 3785 (2002) Abstract; Full Text
[6] The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant: F. Rharbaoui, et al.; Eur. J. Immunol. 32, 2857 (2002) Abstract
[7] Differential recognition of structural details of bacterial lipopeptides by toll-like receptors: M. Morr, et al.; Eur. J. Immunol. 32, 3337 (2002) Abstract
[8] CD14 is required for MyD88-independent LPS signaling: Z. Jiang, et al.; Nat. Immunol. 6, 565 (2005) Abstract
[9] The tumor suppressor CYLD Acts as a Negative Regulator for Toll-like Receptor 2 Signaling via Negative Cross-talk with TRAF6 and TRAF7: H. Yoshida, et al.; J. Biol. Chem. 280, 41111 (2005) Abstract; Full Text
[10] IRF-7 is the master regulator of type-I interferon-dependent immune responses: K. Honda, et al.; Nature 434, 772 (2005) Abstract
[11] The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies: N. Satta, et al.; Blood 109, 1507 (2007) Abstract
[12] Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2: A. Kaufmann, et al.; Infect. Immun. 67, 6303 (1999) Abstract; Full Text
General Information
BACKGROUND/TECHNICAL INFORMATION MALP-2 sticks avidly to glass or plastic. Since it is active at very low concentrations, i.e. at high dilutions, these low amounts of material tend to become adsorbed to pipette tips and plastic or glass containers. To avoid this, prepare several dilution steps of the MALP-2 stock solution with medium containing 5% autologous serum or buffers with 2% HSA. The presence of 50mM octyl glucoside in the first dilution step is often beneficial and gives rise to higher activity. Avoid small volumes in large vessels. Do not filter.
Because of the ester-bound fatty acids, MALP-2 is sensitive to alkali or acid. The medium should be preconditioned in the CO2 incubator in order to ensure that the pH does not become alkaline. Add cells in preconditioned medium as soon as possible and incubate.
MANUFACTURER Licensed from GBF Braunschweig, Germany.
General Literature References
Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages: T. Into, et al.; Infect. Immun. 70, 3586 (2002) Abstract; Full Text
Site-specific proteolysis of the MALP-404 lipoprotein determines the release of a soluble selective lipoprotein-associated motif-containing fragment and alteration of the surface phenotype of Mycoplasma fermentans: K.L. Davis & K.S. Wise; Infect. Immun. 70, 1129 (2002) Abstract; Full Text
Related Products
Further Categories Containing This Product:
Peptides
 
 
ALX-351-001 Revised 08-Apr-08
Paclitaxel
Add to Clipboard
SYNONYMS Taxol®
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Antitumor Reagents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-351-001-M001   1 mg 20.00 USD Add To Cart
ALX-351-001-M005   5 mg 50.00 USD Add To Cart
ALX-351-001-M025   25 mg 150.00 USD Add To Cart
Product Specification
FORMULA: C47H51NO14
MW: 853.9
CAS NUMBER: 33069-62-4
MERCK INDEX: 14: 6982
RTECS: DA8340700
SOURCE/HOST: Isolated from Taxus brevifolia.
PURITY: ≥98%
APPEARANCE: Off-white crystalline powder.
SOLUBILITY: Soluble in acetonitrile, DMSO or methanol; sparingly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Keep cool and dry.
HAZARD: MAY BE MUTAGENIC. HARMFUL. MAY BE TERATOGENIC.
IDENTITY: Determined by IR.

Product Description

Antitumor agent. Binds to tubulin. Promotes assembly and inhibits disassembly of microtubules. Blocks the cell cycle at the mitotic phase and induces apoptosis. The checkpoint of mitotic spindle assembly, aberrant activation of cyclin-dependent kinases (CDKs) and the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) are involved in paclitaxel-induced apoptosis.
Product Specific Literature References
CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells: Y.D. Yoo, et al.; Clin Cancer Res 4, 3063 (1998) Abstract
Molecular effects of paclitaxel: myths and reality (a critical review): M.V. Blagosklonny & T. Fojo; Int. J. Cancer 83, 151 (1999) Abstract
Paclitaxel-induced cell death: where the cell cycle and apoptosis come together: T.H. Wang, et al.; Cancer 88, 2619 (2000) Abstract
Disruption of Cell Adhesion and Caspase-Mediated Proteolysis of beta- and gamma-Catenins and APC Protein in Paclitaxel-Induced Apoptosis:: Y.H. Ling, et al.; Mol. Pharmaco. 59, 593 (2001) Abstract; Full Text
Taxol: biosynthesis, molecular genetics, and biotechnological applications: S. Jennewein and R. Croteau; Appl. Microbiol. Biotechnol. 57, 13 (2001) Abstract
Chemistry and chemical biology of taxane anticancer agents: M.L. Miller and I. Ojima; Chem. Rec. 1, 195 (2001) Abstract
Paclitaxel and its formulations: A.K. Singla, et al.; Int. J. Pharm. 235, 179 (2002) Abstract
Paclitaxel in cancer therapy: T.M. Mekhail and M. Markman; Expert. Opin. Pharmacother. 3, 755 (2002) Abstract
Taxol reactions: K.S. Price and M.C. Castells; Allergy Asthma Proc. 23, 205 (2002) Abstract
The chemistry of taxol and related taxoids: D.G. Kingston, et al.; Fortschr. Chem. Org. Naturst. 84, 53 (2002) Abstract
Overcoming multidrug resistance in taxane chemotherapy: R. Geney, et al.; Clin. Chem. Lab. Med. 40, 918 (2002) Abstract
Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action: M. Abal, et al.; Curr. Cancer Drug Targets 300, 193 (2003) Abstract
Paclitaxel: as adjuvant or neoadjuvant therapy in early breast cancer: D. Simpson & G.L. Plosker; Drugs 64, 1839 (2004), Review Abstract
Paclitaxel for AIDS-associated Kaposi’s sarcoma: T. Dhillon, et al.; Expert Rev. Anticancer Ther. 5, 215 (2005), Review Abstract
Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo: P. Wagner, et al.; Cell Cycle 4, 1149 (2005), Review Abstract
Further Categories Containing This Product:
Taxol/Related Products • Natural Products for Cytoskeletal Research • Microtubule Modulators • TLR Agonists Other Products • Alkaloids
 
 
ALX-165-066 Revised 08-Mar-07
Pam3Cys-Ser-(Lys)4 . trihydrochloride